Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q3 FY25 results · Oct–Dec 2024
Astec LifeSciences reported revenue from operations of ₹93.86 crore (up 84.8% from Q3 FY24) and net loss of ₹40.37 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 93.86 | 50.79 | +84.8% | 98.55 | −4.8% |
| Other income | 1.91 | 0.91 | +110.6% | 2.00 | −4.2% |
| Total income | 95.77 | 51.70 | +85.2% | 100.54 | −4.7% |
| Profit before tax | (25.15) | (32.22) | Loss narrowed | (38.54) | Loss narrowed |
| Net profit for the period | (40.37) | (24.33) | Loss widened | (38.55) | Loss widened |
| Attributable to shareholders of the company | (40.38) | (24.33) | Loss widened | (38.56) | Loss widened |
| EPS, basic (₹) | (20.59) | (12.41) | Loss widened | (19.66) | Loss widened |
| Net margin (%) | -43.0 | -47.9 | -39.1 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 93.86 | 50.79 | +84.8% | 98.55 | −4.8% |
| Other income | 1.89 | 0.90 | +110.3% | 1.98 | −4.5% |
| Total income | 95.75 | 51.69 | +85.2% | 100.53 | −4.8% |
| Profit before tax | (25.18) | (32.25) | Loss narrowed | (38.57) | Loss narrowed |
| Net profit for the period | (40.40) | (24.35) | Loss widened | (38.57) | Loss widened |
| EPS, basic (₹) | (20.60) | (12.42) | Loss widened | (19.67) | Loss widened |
| Net margin (%) | -43.0 | -47.9 | -39.1 |
Consolidated
- Filed with BSE
- 12 Mar 2025, 16:40 IST
- Board meeting
- 27 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Mar 2025, 16:40 IST
- Board meeting
- 27 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE